statins were enrolled in the study. The inclusion criteria were patients who had LDL-C levels greater than 140 mg/dl and more than one CHD risk factor, had LDL-C levels greater than 120 mg/dl and more than three CHD risk factors, or had received pravastatin (5-10 mg/d), simvastatin (5 mg/d), fl uvastatin (20 mg/d), atorvastatin (5-20 mg/d), or pitavastatin (1 mg/d) for more than 3 months. Age (men у 45 years; women у 55 years), hypertension (HT), history of CHD, DM, and smoking were considered as CHD risk factors. Patients with a history of myocardial infarction or stable angina were considered to have CHD. Patients who were receiving antihypertensive therapy or who had systolic blood pressure у 140 mmHg and/or diastolic blood pressure у 90 mmHg were considered to have hypertension. Patients who were receiving antidiabetic therapy or who had fasting blood glucose concentrations у 126 mg/dl and/or 2-h glucose concentration у 200 mg/dl after an oral glucose tolerance test were considered to have DM. Current smokers were considered to have smoking as a CHD risk factor. Men had a higher prevalence of CHD (59.4% vs. 26 .5%) and a higher percentage of patients with у 3 risk factors of CHD (46.9% vs. 22.4%) than women. Exclusion criteria included: a history of allergy with statin treatment; liver diseases, including cirrhosis; severe renal disease complications, including diabetic nephropathy and renal failure; acute myocardial infarction; unstable angina; LDL apheresis; receiving nicotinic acid; and immunosuppressant and hormone therapy. The study protocol was approved by the Ethics Committee of Fukuoka University Hospital, and written informed consent was obtained from all patients.
All of the patients were treated with low-dose (2.5 mg/d) rosuvastatin for 3 months, and patients who were receiving other statins (75.0% of the men and 87.8% of the women) were switched to treatment with 2.5 mg rosuvastatin. Overnight fasting blood was drawn at baseline and after treatment with rosuvastatin for 3 months. Plasma containing 2 mM EDTA was separated for the measurement of lipid and lipoproteins.
Separation of plasma d>1.006 g/ml and d>1.040 g/ml fractions by quantitative ultracentrifugation Plasma d>1.006 g/ml fraction, which was depleted of very-lowdensity lipoprotein (VLDL) and contained classically defi ned LDL particles, i.e., intermediate-density lipoprotein (d 1.006-1.019 g/ml) and the bulk of LDL (d 1.019-1.063 g/ml) ( 24 ) , and d>1.040 g/ml fraction (depleted of TRL and large, buoyant LDL) were separated by quantitative ultracentrifugation for measurement of the LDL and sdLDL compositions and cITP LDL and sdLDL subfractions, as described previously ( 19 ) .
Measurement of charge-based LDL subfractions by cITP
Lipoprotein subfractions were analyzed in EDTA plasma by cITP on a Beckman P/ACE MDQ system (Beckman-Coulter Inc., Tokyo, Japan) as described previously ( 18, 19, 22 ) . cITP LDL and sdLDL subfractions were analyzed in plasma d>1.006 g/ml and d>1.040 g/ml fractions, respectively ( 19 ) . Six l of plasma or plasma fraction was used for routine analysis. Plasma lipoproteins were prestained with a lipophilic dye, NBD C 6 -ceramide (Molecular Probes, Inc., Eugene, OR), before separation. Levels of cITP lipoprotein subfractions were expressed as the peak area relative to that of an internal marker, 5-carboxy-fl uorescein ( 18, (20) (21) (22) .
Measurement of plasma levels of lipids, lipoproteins, and apolipoproteins, activities of lipoprotein-associated enzymes, the sizes of HDL and LDL, and CRP concentrations Plasma levels of free cholesterol (FC), TG, phospholipids (PL), HDL-C, and LDL-C were measured by enzymatic methods ( 8, (11) (12) (13) . LDL(-) in human plasma is formed from multiple origins ( 6 ) . The infl ammatory marker lipoprotein-associated phospholipase A 2 [also called platelet-activating factor acetylhydrolase (PAF-AH)] has been shown to be associated with LDL(-) ( 14 ) . The clinical importance of LDL(-) is still unknown, as the chromatography technique requires the isolation of LDL from plasma for LDL(-) analysis and thus is labor intensive and time-consuming ( 7, 8, 13 ) , which limits its use as a routine analytical technique. However, it may be important to reduce plasma levels of LDL(-), an atherogenic lipoprotein that resides in plasma longer than normal LDL due to its lower affi nity for LDL receptors ( 15 ) .
Capillary isotachophoresis (cITP) is an analytical technique for analyzing charge-based lipoprotein subfractions directly in plasma (16) (17) (18) . It is advantageous to analyze LDL subfractions in the presence of HDL and plasma proteins because they protect LDL from artifi cial modifi cation. The cITP technique separates plasma lipoproteins into three high-density lipoprotein (HDL) subfractions [fast-, intermediate-, and slow-migrating HDL (fHDL, iHDL, and sHDL)], two triglyceride (TG)-rich lipoprotein (TRL) subfractions [fast-and slow-migrating TRL (fTRL and sTRL)], and two major LDL subfractions [fast-and slow-migrating LDL (fLDL and sLDL)] according to their electrophoretic mobilities ( 18, 19 ) . The levels of cITP LDL subfractions can be determined as peak areas relative to that of an internal marker (18) (19) (20) (21) (22) .
We have previously shown that cITP fLDL is an electronegative LDL subfraction because fLDL is increased and sLDL is decreased when LDL is mildly oxidized ( 19 ) . Our recent study ( 23 ) showed that cITP fLDL levels were elevated in patients with HC and risk factors of CHD and were effectively reduced by low-dose pravastatin and simvastatin (The SPECIAL study).
We previously found that a new electronegative LDL subfraction that has faster electrophoretic mobility than cITP fLDL was increased when LDL was moderately oxidized, and defi ned this more electronegative LDL subfraction as veryfast-migrating LDL (vfLDL) ( 19 ) . We observed drastically increased cITP vfLDL in patients with extremely low levels of HDL-C and low levels of LDL-C ( 19 ) . The cITP vfLDL comigrates with cITP sTRL in human plasma and therefore needs to be analyzed in plasma depleted of TRL. It has not yet been determined whether the more electronegative LDL subfraction (cITP vfLDL) is increased in patients with HC and could be effectively reduced by statin treatment.
In the present study, we examined the effects of rosuvastatin on cm-LDL subfractions of LDL (vfLDL and fLDL) and sdLDL (sd-vfLDL and sd-fLDL) as analyzed by cITP and the relation of the effects of rosuvastatin on LDL particle concentrations and HDL-C levels in HC patients with CHD or risk factors for CHD.
METHODS

Patients
Eighty-one outpatients (32 men and 49 women) with CHD or risk factors for CHD and HC or who were being treated with by guest, on October 13, 2017 www.jlr.org Downloaded from treatment increased lipid and protein contents in HDL and decreased those in LDL and sdLDL. Particle concentrations of LDL and sdLDL, measured as LDL-apoB and sdLDL-apoB concentrations, were reduced similarly in men and women (LDL-apoB, Ϫ 17% and Ϫ 16%; sdLDLapoB, Ϫ 21% and Ϫ 19%).
Distribution of charge-based LDL and sdLDL subfractions as analyzed by cITP in HC patients with similar LDL-C and sdLDL-C levels Figure 1 shows typical lipoprotein subfractions in plasma from a normolipidemic (NL) volunteer subject (TG, HDL-C, and LDL-C, 49, 60, and 91 mg/dl, respectively), a patient with HC (139, 51, and 146 mg/dl), and a diabetic patient with HTG and HC (355, 54, and 147 mg/dl), as analyzed by cITP. As shown, the HC patient ( Fig. 1B .a) and the HTG-HC patient ( Fig. 1C .a) had increased cITP fLDL (peak 6) in plasma compared with the NL subject ( Fig. 1A ) , and the HTG patient had apparently increased cITP fTRL and sTRL (peaks 4 and 5) compared with the HC patient, as expected. However, although the HC and HTG-HC patients had similar LDL-C levels (146 and 147 mg/dl, respectively), they had apparently different distributions of cITP LDL subfractions ( Figs. 1B .b, C.b). The cITP vfLDL (peak 5) was the minor LDL subfraction and sLDL (peak 7) was the major LDL subfraction in plasma d>1.006 g/ml fraction from the HC patient ( Fig. 1B .b ), but cITP vfLDL was drastically increased and the three cITP LDL subfractions, vfLDL, fLDL, and sLDL, were evenly distributed in plasma d>1.006 g/ml fraction from the HTG-HC patient ( Fig. 1C .b) .
The distributions of cITP sdLDL subfractions as analyzed in plasma d>1.040 g/ml fraction were similar to those of LDL subfractions in the same patients except that the proportion of sd-fLDL was greater than that of fLDL ( Figs. 1.B, C ) . However, the distributions of cITP sdLDL subfractions in the HC and HTG-HC patients ( Figs. 1B .c, C.c) were drastically different despite similar sdLDL-C levels (67 and 74 mg/dl, respectively).
Therefore, the levels of cITP vfLDL and fLDL subfractions and cITP sd-vfLDL and sd-fLDL could not be predicted based on LDL-C and sdLDL-C levels.
Effects of rosuvastatin on charge-based LDL and sdLDL subfractions as analyzed by cITP
In all of the patients, the proportions of cITP vfLDL and fLDL in total LDL as measured in plasma d>1.006 g/ml fraction were 8.4 ± 0.6% and 25.0 ± 0.8%, respectively. As shown in Table 2 , rosuvastatin treatment significantly decreased cITP fLDL and sLDL subfractions in whole plasma, vfLDL, fLDL, and sLDL subfractions in plasma d>1.006 g/ml fraction, and sd-vfLDL, sd-fLDL, and small, dense, slow-migrating LDL (sd-sLDL) subfractions in both men and women. The proportion of fLDL or sd-fLDL was not signifi cantly affected (data not shown). Rosuvastatin caused similar reductions in vfLDL and fLDL subfractions ( Ϫ 18% and Ϫ 22%) and reductions in sdvfLDL and sd-fLDL subfractions ( Ϫ 24% and Ϫ 20%) in all of the patients.
as described previously ( 19 ) . Plasma remnant-like particle cholesterol (RLP-C) levels were measured using a MetaboLead RemL-C reagent kit for an autoanalyzer, kindly provided by Kyowa Medex, Tokyo, Japan. Plasma levels of apolipoprotein (apo)A-I, apoB, apoC-II, and apoE were measured by turbidimetric immunoassay methods as described previously ( 22 ) .
Serum basal paraoxonase (PON1) activity was measured on an autoanalyzer (Hitachi 7600-020S; Hitachi High-Technologies, Tokyo, Japan) with paraoxon as a substrate, as described previously ( 25 ) . Plasma PAF-AH activity was measured using an Azwell Auto PAF-AH reagent kit (Alfresa, Osaka, Japan) as described previously ( 26 ) .
ApoB-depleted plasma was separated using the phosphotungstate-Mg 2+ precipitation method, as described previously ( 27 ) , for measurement of HDL-FC, HDL-PL, and HDL-associated PAF-AH (HDL-PAF-AH) activity. LDL-associated PAF-AH (LDL-PAF-AH) activity was calculated from PAF-AH activities in whole plasma and apoB-depleted plasma ( 26 ) .
Particle concentrations of LDL and sdLDL were measured as apoB levels in plasma d>1.006 g/ml and d>1.040 g/ml fractions. sdLDL-C levels were measured as LDL-C levels in plasma d>1.040 g/ml fraction. Levels of LDL-FC and LDL-PL or levels of sdLDL-FC and sdLDL-PL were calculated from FC and PL levels measured in plasma d>1.006 g/ml fraction or d>1.040 g/ml fraction and apoB-depleted plasma.
HDL and LDL particle sizes were measured by composite gradient gel electrophoresis as described previously ( 19, (28) (29) (30) .
Serum CRP concentrations were measured in a 'high-sensitivity' assay using particle-enhanced immunonephelometry with N-latex CRPII (Dade Behring Marburg GmbH, Marburg, Germany).
Statistical analysis
All of the data analyses were performed using the SAS (Statistical Analysis System) Software Package (Ver. 9.1.3, SAS Institute Inc.., Cary, NC) at Fukuoka University (Fukuoka, Japan). The normality of the distribution of continuous variables was examined by the Shapiro-Wilk test. Changes in continuous variables during the study period were examined by the Wilcoxon signedrank test. Data are presented as mean ± standard error (SE) and median values are given for percentage changes. The Spearman correlation was used to examine the correlation among continuous variables. Signifi cance was considered to be a P value of less than 0.05 unless indicated otherwise.
RESULTS
Effects of rosuvastatin on the compositions of HDL, LDL, and sdLDL and plasma levels of TG, RLP-C, apolipoproteins, and infl ammatory markers
As shown in Table 1 , treatment with 2.5 mg rosuvastatin for 3 months increased plasma levels of HDL-C, HDL-FC, HDL-PL, apoA-I, and HDL-PAF-AH activity in all of the patients without signifi cantly affecting serum PON1 activity or the size of HDL. Rosuvastatin decreased plasma levels of LDL-C, LDL-FC, LDL-PL, and LDL-apoB, LDL-PAF-AH activity, and levels of sdLDL-C, sdLDL-FC, sdLDL-PL, and sdLDL-apoB without affecting the size of LDL. Rosuvastatin also signifi cantly decreased the ratio of LDL-C to HDL-C (LDL-C/HDL-C), plasma levels of TG, RLP-C, apoB, apoC-II, and apoE, and plasma PAF-AH activity without signifi cantly affecting serum CRP concentrations in all of the patients ( Table 1 ) . Therefore, rosuvastatin Pathophysiological relevance of the different LDL and sdLDL subfractions as analyzed by cITP Table 3 shows the relation between levels of cITP LDL and sdLDL subfractions and the compositions of HDL, LDL, and sdLDL or plasma levels of TG, RLP-C, apolipoproteins, and infl ammatory markers in all of the patients at baseline. Levels of cITP fLDL and sLDL analyzed in whole plasma and in plasma d>1.006 g/ml fraction were strongly correlated ( r = 0.95 and 0.95, respectively), as expected ( Table 3 ) . cITP fLDL and vfLDL subfractions of LDL or sdLDL, as measured in plasma d>1.006 g/ml or d>1.040 g/ml fractions, were strongly correlated with each other ( r = 0.93 or 0.93), but were not correlated with the Figure 2 shows box-and-whisker plots of the percentage changes in the cITP LDL subfraction in whole plasma and the plasma d>1.006 g/ml fraction and cITP sdLDL subfraction in the d>1.040 g/ml fraction caused by rosuvastatin. As shown, the median percentage changes in the three subfractions of LDL (vfLDL, fLDL, and sLDL) or sdLDL (sd-vfLDL, sd-fLDL, and sd-sLDL) were similar in all of the patients and in female and male patients, respectively, but the percentage changes in cITP vfLDL or sdvfLDL for all of the patients varied to a greater extent compared with fLDL and sLDL or sd-fLDL and sd-sLDL due to the relatively low levels of cITP vfLDL and sd-vfLDL ( Table 2 ) . levels of TG, RLP-C, apoC-II, and apoE, whereas sLDL and sd-sLDL were not related to these TRL-related variables ( Table 3 ) . Therefore, cITP cm-LDL subfractions of LDL (vfLDL and fLDL) and sdLDL (sd-vfLDL and sd-fLDL) were closely related to each other, but were different from the normal LDL subfraction of LDL (sLDL) and sdLDL (sdsLDL) with regard to LDL size and TG-related variables. Accordingly, the vfLDL and fLDL subfractions were combined in the following statistical analyses.
Relation between the effects of rosuvastatin on cITP cm-LDL and sd-cm-LDL subfractions and HDL-C levels, LDL particle concentrations, and TRL-related variables Table 4 shows the relation between the percentage changes in cITP cm-LDL (vfLDL + fLDL) and sLDL subfractions of LDL and sdLDL and those in the compositions of HDL, LDL, and sdLDL and plasma levels of TG, RLP-C, and apolipoproteins in all of the patients during the study. The percentage changes in cm-LDL and sd-cm-LDL were negatively correlated with those in HDL-C ( r = Ϫ 0.25 and sLDL subfraction of LDL ( r = Ϫ 0.03) or sdLDL ( r = 0.22). Therefore, the two cm-LDL subfractions of LDL and sdLDL were closely related to each other but were not related to the normal subfraction (sLDL) of LDL or sdLDL.
cITP cm-LDL subfractions of LDL (vfLDL, fLDL) and sdLDL (sd-vfLDL, sd-fLDL) were negatively correlated with HDL-PAF-AH activity, and all of the three cITP sdLDL subfractions (sd-vfLDL, sd-fLDL, and sd-sLDL) were negatively correlated with HDL-C, HDL-FC, and HDL-PL levels and HDL size ( Table 3 ) .
Both cITP fLDL and sLDL subfractions of LDL or sdLDL were positively correlated with cholesterol, FC, PL, and apoB concentrations of LDL or sdLDL ( Table 3 ) . However, whereas cITP cm-LDL subfractions (vfLDL and fLDL) and sd-cm-LDL subfractions (sd-vfLDL and sdfLDL) were negatively correlated with the size of LDL ( r = Ϫ 0.34, Ϫ 0.29, Ϫ 0.51, and Ϫ 0.51), cITP sLDL was positively correlated with LDL size ( r = 0.27) and sd-sLDL was not correlated with LDL size ( r = Ϫ 0.02) ( Table 3 ) .
Also, cITP vfLDL and fLDL subfractions and sd-vfLDL and sd-fLDL subfractions were positively correlated with acid ( 34 ) . This atherogenic lipoprotein is formed from multiple origins ( 6 ) and resides in plasma longer than normal LDL due to its lower affi nity for LDL receptors ( 15 ) . Although the clinical signifi cance of LDL(-) is still not clear, it may be important to examine the effects of statins on the levels of LDL(-), an integrated index for various forms of atherogenic modifi ed LDL in plasma including OxLDL, sdLDL, and glycated LDL.
Normally, fLDL subfraction in human plasma is analyzed by cITP as LDL(-) ( 18, 19, 22 ) . Our previous study ( 23 ) showed that two commonly used statins, pravastatin and simvastatin, effectively reduced cITP fLDL in patients with HC and risk factors of CHD (the SPECIAL study). However, when plasma d>1.006 g/ml fraction (depleted of TRL) and d>1.040 g/ml fraction (contains sdLDL) from a patient with HDL defi ciency were analyzed, we found that a new LDL(-) subfraction that had faster electrophoretic mobility than fLDL, i.e., vfLDL, was drastically increased ( 19 ) . This more electronegative LDL subfraction, vfLDL, was also observed in patients with HC ( Fig. 1 ) . Since the cITP vfLDL subfraction had the same electrophoretic mobility as the sTRL subfraction in plasma, the vfLDL subfraction cannot be measured in whole plasma but needs to be analyzed in plasma depleted of TRL ( Fig. 1 ) . The present study examined the effects of rosuvastatin on the levels of cITP vfLDL subfraction and sd-cm-LDL subfractions, which are the presumably most atherogenic modifi ed LDL, and examined the relation among the three charge-based subfractions of LDL (vfLDL, fLDL, and sLDL) and sdLDL (sd-vfLDL, sd-fLDL, and sd-sLDL).
We demonstrated that the distribution of charge-based LDL subfractions could not be predicted from the LDL-C level because the two HC patients who had similar LDL-C levels had drastically different distributions of chargebased subfractions of LDL ( Fig. 1 ) . We showed that sdLDL, Ϫ 0.28), and the percentage changes in cITP sd-cm-LDL were also negatively correlated with those in HDL-PL and apoA-I ( Table 4 ) .
The percentage changes in both cm-LDL and sLDL were positively correlated with those in LDL-related variables (LDL-C, LDL-FC, LDL-PL, LDL-apoB, and LDL-PAF-AH) and LDL-C/HDL-C, and the percentage changes in both sd-cm-LDL and sd-sLDL were positively correlated with those in sdLDL-C, sdLDL-PL, and sdLDL-apoB ( Table 4 ) .
Although the percentage changes in cm-LDL and sdcm-LDL were also positively correlated with those in TG, RLP-C, apoC-II, and apoE, the percentage changes in sLDL and sd-sLDL were not correlated with those in TRLrelated variables ( Table 4 ) . Therefore, the reducing effects of rosuvastatin on both cm-LDL and normal LDL subfractions were related to the reduction in LDL particle concentrations. However, the reducing effects of rosuvastatin on cm-LDL were also related to changes in HDL-C and TRL-related variables. DISCUSSION An increased LDL-C level is an established risk factor for CHD. Although the ability of LDL-C to predict the risk for CHD is moderate, the reduction of LDL-C levels by lipid-lowering drugs (statins) has consistently been shown to reduce cardiovascular events in primary and secondary prevention. Infl ammatory processes play a central role in the progression of atherosclerosis and plaque rupture ( 31 ) . Statins have been shown to decrease CRP ( 2, 3 ) and improve the antiinfl ammatory potential of HDL ( 32, 33 ) .
LDL(-), a cm-LDL subfraction in human plasma, has been shown to be infl ammatory due to its increased content of lysophosphatidylcholine and nonesterifi ed fatty We observed strong correlations between cITP fLDL measured in whole plasma and plasma d>1.006 g/ml fraction ( Table 3 , r = 0.95) and between cITP vfLDL and fLDL measured in plasma d>1.006 g/ml fraction ( Table 3 , r = 0.93). Therefore, the measurement of cITP fLDL in plasma should be suffi cient in routine clinical practice, also considering that changes in physicochemical properies may occur during the ultracentrifugation of lipoproteins.
This study is the fi rst to show that low-dose rosuvastatin effectively and similarly reduced both cITP vfLDL and fLDL subfractions of LDL and sdLDL in HC patients with CHD and risk factors of CHD ( Table 2 ) . Although the reduction of cm-LDL and sd-cm-LDL may represent a novel pleiotropic effect of rosuvastatin, the mechanism for these effects is still not clear. It is possible that the clearance of cm-LDL via LDL receptor may be increased. It is well known that statins up-regulate the number of LDL receptors due to the inhibition of cellular cholesterol synthesis. Simvastatin has been shown to increase the affi nity of LDL(-) for LDL receptors in patients with familial hypercholesterolemia ( 35 ) . In the present study, we found that the percentage changes in similar to plasma LDL, also contained LDL subfractions that had different electrophoretic mobilities (cITP sdvfLDL, sd-fLDL, and sd-sLDL) ( Fig. 1 ) , and that the distribution of charge-based sdLDL subfractions could also not be predicted from the sdLDL-C level.
To clarify whether the cm-LDL and normal LDL subfractions may have different physiological relevance, we examined the relation among the three charge-based subfractions of LDL and sdLDL and their relation to plasma lipidrelated variables at baseline ( Table 3 ). All of the three cITP subfractions of LDL (vfLDL, fLDL, and sLDL) or sdLDL (sd-vfLDL, sd-fLDL, and sd-sLDL) were correlated with cholesterol content and particle concentrations of LDL or sdLDL ( Table 3 ) , as expected. However, our fi ndings indicates that cm-LDL and normal LDL are discrete LDL subfractions, because charge-modifi ed subfractions of LDL (vfLDL and fLDL) and sdLDL (sd-vfLDL and sd-fLDL) were very closely related to each other but were apparently different from the normal LDL subfraction of LDL (sLDL) or sdLDL (sd-LDL) with regard to their relation to LDL size, TG, RLP-C, apoC-II, and apoE ( Table 3 ) . Another possible mechanism by which rosuvastatin reduces cm-LDL and sd-cm-LDL may be related to its effects on HDL. Simvastatin has been shown to improve the antiinfl ammatory potential of HDL ( 32, 33 ) . In the present study, we showed that rosuvastatin not only signifi cantly increased HDL-C levels but also increased plasma levels of apoA-I, the major protein of HDL, by about 3% and HDL-PL by about 8% (Table 1) . Our previous in vitro experiments showed that pitavastatin drastically reduces cellular free cholesterol and increases mRNA apoA-I levels in HepG2 cells ( 38 ) . Therefore, it is possible that rosuvastatin may increase the secretion of nascent HDL, which is lipid poor and contains apoA-I and PL. Our previous in vitro experiment showed that apoA-I/phosphatidylcholine discs reduce cm-LDL as analyzed by cITP ( 19 ) . Nascent HDL may remodel LDL by causing the movement of lipid, lipid peroxides, enzyme, and/or protein from LDL to HDL ( 19, 39 ) , thus reducing sd-cm-LDL.
In conclusion, rosuvastatin effectively reduced both the fLDL and vfLDL subfractions of LDL and sdLDL. Further cm-LDL and sd-cm-LDL were correlated with the particle concentrations of LDL and sdLDL, measured as LDL-apoB and sdLDL-apoB, respectively ( Table 4 ) .
It is also possible that cm-LDL derived from VLDL remnant particles may be reduced by rosuvastatin. Pitavastatin, another strong statin, has been shown to decrease the secretion of apoB from HepG2 cells ( 36 ) and to reduce VLDL secretion in Watanabe heritable hyperlipidemic rabbits ( 37 ) , an animal model of familial hypercholesterolemia. We showed that both the common statins pravastatin and simvastatin ( 23 ) , and rosuvastatin ( Table 1 ) effectively reduced RLP-C levels. We consistently found an association between cITP fLDL and RLP-C in patients with HC in our previous studies ( 22, 23 ) and in the present study ( Table 3 ) . Other authors have shown that LDL(-) had increased contents of TG, apoE, and apoC-III ( 8 ) . In the present study, we also found that the percent reductions in cm-LDL and sd-cm-LDL subfractions caused by rosuvastatin treatment were correlated with those in TG, RLP-C, apoC-II, and apoE. Therefore, it is clear that a link exists between cm-LDL and TRL. 
